ArticleCureus2025
Hyperkalemia Caused by Potassium-Enriched Salt in a Hospitalized Patient.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperkalemia is a potentially life-threatening condition, particularly in patients with chronic kidney disease (CKD). Potassium-enriched salt substitutes are increasingly promoted as a dietary intervention for hypertension, but may pose risks in patients with impaired renal function. We report the case of an 88-year-old male with CKD who developed asymptomatic but marked hyperkalemia (7.5 mEq/L) during hospitalization for osteomyelitis. The patient had unknowingly consumed a potassium-enriched salt substitute brought in by his family to improve the taste of hospital meals. His renal function had previously declined due to septic and prerenal acute kidney injury. Following identification of the hyperkalemia, the patient was treated with glucose-insulin therapy, intravenous fluids, diuretics, and sodium polystyrene sulfonate, leading to normalization of serum potassium levels. This case highlights the importance of monitoring dietary potassium sources in hospitalized patients with CKD and underscores the need for patient and caregiver education regarding the risks of unregulated dietary supplements, especially potassium-based salt substitutes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.